Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2644 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-01-28 (medpagetoday.com)
Mold and Parkinson's? Cannabis and Brain Function; Women and Long COVID Risk | MedPage Today
News and commentary from the world of neurology and neuroscience
Read more
2025-01-21 (outsourcedpharma.com)
RNA Therapeutics As We Enter 2025 Looking Beyond The Horizon Of First-Generation Success
As we enter 2025, RNA therapeutics are poised to command significant attention from industry leaders as well as emerging players.
Read more
2024-10-01 (hoy.com.py)
Study reveals that severe COVID-19 accelerates brain aging
A study reveals that patients hospitalized with COVID-19 may suffer cognitive decline equivalent to 20 years of brain aging, raising concerns about the long-term sequelae of the disease.
Read more
2024-08-13 (pharmavoice.com)
A potential MS ‘game changer’ could bring more safety to the table — even against viruses
Immunic’s treatment has anti-inflammation, neuroprotection and antiviral effects plus a ‘benign’ safety profile that even seems to lower the risk of COVID-19 infection.
Read more
2024-08-01 (labiotech.eu)
CureVac: From a failed drug to a €400 million deal
After a 2021 setback with its mRNA-based COVID-19 vaccine, CureVac turned things around with a key deal with GSK. Discover how.
Read more
2024-02-28 (pharmaceutical-technology.com)
Beyond approval: Patients pursue alternate paths to get rare disease treatments -
As post-approval boundaries disproportionately affect rare disease patients, communities are rallying behind alternative options.
Read more
2024-02-20 (washingtonpost.com)
Lab spaces boomed during the pandemic. Then the experiment took a turn.
Around Boston, a glut of lab space is just the latest example of how the U.S. economy zigged when just about everyone thought it would zag.
Read more
2024-02-14 (statnews.com)
Replicate's srRNA rabies vaccine effective in Phase 1
Replicate Bioscience's self-replicating RNA rabies vaccine induced strong immune responses in a Phase 1 clinical trial, even at extremely low doses. Notably, the doses contained fractions of the volume found in the mRNA Covid shot.
Read more
2024-01-12 (pharmaceutical-technology.com)
FDA yet to find link between suicidal risk and GLP-1RA use
The leading site for news and procurement in the pharmaceutical industry
Read more